Skip to main content
. 2017 Feb 24;7:43139. doi: 10.1038/srep43139

Figure 4. BET bromodomain inhibition via CPI-203 treatment alters goblet cell hyperplasia and mucus production in the lungs of mice with Th17-induced allergic airway disease.

Figure 4

(A) Pulmonary expression of Muc5ac and (B) Clca3 as well as (C) representative images of Periodic Acid Schiff (PAS)-stained lung sections (200x magnification) from OVA-treated BALB/c SCID mice that received Th17 cells (Th17 group) or PBS (control group) with and without CPI-203 treatment. (D) Mucus production in the PAS-stained lung sections was quantified by an observer blinded to the identity of the samples. Data shown for control (n = 5), CPI-203 (n = 6), Th17 (n = 8), Th17+ CPI-203 (n = 8) combined from three independent experiments. *p < 0.05 when compared to control and CPI-203 group, †p < 0.05 when compared to all other groups.